Cipher Pharmaceuticals Inc.

DB:PHE Stock Report

Market Cap: €255.6m

Cipher Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

Cipher Pharmaceuticals has been growing earnings at an average annual rate of 43%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 0.1% per year. Cipher Pharmaceuticals's return on equity is 16%, and it has net margins of 59.9%.

Key information

43.0%

Earnings growth rate

44.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-0.1%
Return on equity16.0%
Net Margin59.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cipher Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:PHE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24261690
30 Jun 24222360
31 Mar 24222360
31 Dec 23212050
30 Sep 23213250
30 Jun 23202850
31 Mar 23202750
31 Dec 22212750
30 Sep 22221050
30 Jun 2221850
31 Mar 2222950
31 Dec 2122850
30 Sep 2122560
30 Jun 2123660
31 Mar 2121360
31 Dec 2022460
30 Sep 2021760
30 Jun 2022350
31 Mar 2023460
31 Dec 1922380
30 Sep 1923-1110
30 Jun 19222130
31 Mar 19233141
31 Dec 18231141
30 Sep 18286131
30 Jun 18349130
31 Mar 183711130
31 Dec 174011130
30 Sep 17347130
30 Jun 17325130
31 Mar 17311141
31 Dec 16304161
30 Sep 16336231
30 Jun 16342280
31 Mar 16341290
31 Dec 15342291
30 Sep 15323211
30 Jun 153013141
31 Mar 153018101
31 Dec 14291991
30 Sep 14333171
30 Jun 14322771
31 Mar 14292570
31 Dec 13252460

Quality Earnings: PHE has a high level of non-cash earnings.

Growing Profit Margin: PHE's current net profit margins (59.9%) are lower than last year .


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PHE has become profitable over the past 5 years, growing earnings by 43% per year.

Accelerating Growth: PHE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PHE had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).


Return on Equity

High ROE: PHE's Return on Equity (16%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies